An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Cognizant and Palo Alto Networks are partnering to deliver AI-driven cybersecurity capabilities and services for enterprises ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

In less than a month, Americans will head to the polls—or vote by mail—and elect the next president of the U.S. | While a ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Leaders of Gritstone Bio Inc. could read the writing on the wall: Financial times for drug developers are tough and the ...